136
Participants
Start Date
December 1, 2018
Primary Completion Date
November 8, 2022
Study Completion Date
November 8, 2022
Loncastuximab Tesirine
Intravenous (IV) infusion.
Ibrutinib
Oral capsule.
GasthuisZusters Antwerpen Sint-Augustinus, Wilrijk
CHU UCL Namur (Site Godinne), Yvoir
IRCCS istituto Clinico Humanitas U.O. di Oncologia ed Ematologia, Via Manzoni
Istituto Europeo di Oncologia, Milan
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Azienda Ospedaliera Pap Giovanni XXIII, Bergamo
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
The Blood and Marrow Transplant Group of Georgia, Atlanta
Georgia Cancer Center at Augusta University, Augusta
University of Miami, Miami
Miami Cancer Institute, Miami
Hôpital Saint-Eloi, Montpellier
Centre Hospitalier Universitaire de Rennes Hôpital Pontchailou, Bretagne
Hospital Universitario Marqués de Valdecilla, Santander
Policlinico Sant'Orsola Malpighi, Bologna
Norton Cancer Institute, St. Matthews Campus, Louisville
Hospital Universitario Virgen del Rocio, Seville
Hôpital Hôtel-Dieu, Loiré
Case Western Reserve University, Cleveland
Istituto Scientifico Rmagnolo per lo Studio e la Cura dei Tumori, Meldola FC
Azienda Unita Sanitaria Locale de Ravenna, Ravenna
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Minnesota, Minneapolis
Saint Vincent Healthcare, Billings
Centre Hospitalier Lyon Sud, Pierre-Bénite
Hôpital Saint-Louis, Paris
Centre Hospitalier Universitaire De Poitier - Hopital De La Miletrie - Hopital Jean Bernard, Poitiers
Redlands Community Hospital, Redlands
University of California Irvine Health Chao Family Comprehensive Cancer Center, Orange
Hospital Universitario Vall d'Hebrón, Barcelona
Hospital Duran I Reynals, Barcelona
The Christie NHS Foundation Trust, Manchester
Abertawe Bro Morgannwg University Health Board, Swansea
Lead Sponsor
ADC Therapeutics S.A.
INDUSTRY